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Introduction 
Currently, 5.3 million Americans are living with Alzheime~s disease 
(AD).1 AD is the most common cause of dementia and causes up to 50-
80 percent of dementia cases according to the National Institute on Ag-
ing. 2The disease is named after Dr. Alois Alzheimer, who first described 
amyloid plaques and neurofibrillary tangles. Neurofibrillary tangles begin 
to form in the entorhinal cortex and, along with plaque development in 
other areas of the brain, lead to neuronal damage, eventually causing 
malfunction and death of the neuron. Damage to the brain begins 10 to 
20 years before onset of symptoms. The damage eventually spreads 
to the hippocampus, and, as the extent of damage and neuron death 
increases, the size of the brain decreases. 
Although the cause of AD is still unclear, scientists have identified 
several probable causes, including genetic, environmental and lifestyle 
factors.2 Familial AD is caused by mutations on certain chromosomes, 
which results in the formation of abnormal amyloid precursor protein 
(APP), the precursor for beta-amyloid. Other genetic mutations increase 
the amount of beta-amyloid formed, which accumulates to form plaques. 
Another genetic risk factor, SORL 1, was discovered in 2007 and is 
responsible for the transportation of APP within cells. When present 
at low levels, the levels of beta-amyloid increase, increasing the harm 
to neurons. Current research on AD is focusing on the link between 
cognitive decline and heart disease, high blood pressure, diabetes and 
obesity. One theory examines decreased blood flow to the brain associ-
ated with high blood pressure and high cholesterol. This may result in 
decreased glucose metabolism and an increase in BACE1, the enzyme 
that cleaves APP, thus causing beta-amyloid deposition.3 Scientists 
also are investigating lifestyle factors that may improve the outcome 
and progression of patients with AD. The National Institute on Aging 
recommends a nutritious diet, exercise, social engagement and mentally 
stimulating pursuits as lifestyle factors that might help reduce the risk of 
cognitive decline and AD.2 
Current Treatment 
Four drugs are currently indicated for the treatment of AD: donepezil 
(Aricept®), rivastigmine (Exelon®), galantamine (Razadyne®) and 
memantine (Namenda®). These drugs assist in controlling neurotrans-
mitter release, which may decrease symptoms, but do not treat the 
underlying cause of AD.2 Donepezil, rivastigmine and galantamine are 
acetylcholinesterase inhibitors. Inhibiting acetylcholinesterase increases 
the amount of acetylcholine available to neurons in the brain.1 Acetylcho-
line is important for learning and memory. The disease destroys cells 
that synthesize and use acetylcholine. Donepezil is approved to treat 
all stages of the disease, whereas rivastigmine and galantamine are 
approved to treat mild to moderate AD. Memantine works by regulating 
glutamate activity and is approved for treatment of moderate to severe 
AD. Current treatment is aimed at maintaining cognitive function and 
slowing the progression of the disease. However, new research is focus-
ing on the cause of the disease rather than treating the symptoms and 
progression of the disease after onset.2 
New Approaches 
In a normally functioning brain, glucose is the primary energy source, 
and the contribution made by fatty acids is considered small.4 Glucose 
undergoes aerobic oxidation to form carbon dioxide and water. In a brain 
with AD, a decrease in the cerebral metabolic rate of glucose (CMR-
glu) is observed early on in the process. This disturbance is known as 
glucose hypometabolism and has been found to occur in some patients 
decades before the symptoms of AD develop. Because hypometabolism 
occurs early and is progressive, it is a reasonable target in the treatment 
of AD, with a therapeutic goal of increasing the neuronal energy state. 
One way to reach this goal would be to maintain elevated glucose levels 
by using insulin sensitizers and, in some cases, insulin. However, this 
method is associated with significant risks, such as hypoglycemia and 
the lack of compliance of the patient population causing investigations 
into alternative energy sources. 
Ketone bodies cause hyperketonemia, which can be safely induced and 
maintained for several hours compared to hypoglycemia. Ketone bodies 
readily cross the blood brain barrier and are metabolized by neurons. 
For decades, ketogenic diets have been used in epilepsy and Parkin-
son's disease as a way to decrease blood glucose levels and increase 
ketone bodies. These diets normally consist of 88 percent fat, 1 O percent 
protein and 2 percent carbohydrates. When used in the management of 
seizures, 53.9 percent of patients had more than a 75 percent reduction 
in seizures one month after starting the diet. Parkinson's patients using 
this type of diet also showed improvement in motor scores in patients 
with increased ketone levels after 28 days. Although the diet showed 
improvements in these central nervous system diseases, it is impractical 
for chronic use because of the high fat intake, high number of calories 
and an unpalatable regimen. 
Caprylldene 
One of the major ketone bodies in humans is beta-hydroxybuterate 
(BHB). The main benefit of BHB is its conversion to acetoacetate (ACA) 
in the mitochondria. This generates a reducing equivalent of NADH, 
which increases energy in this redox couple. Conversion of ACA to 
acetyl-CoA then generates succinate, a substrate for complex II, which 
allows for possible bypass of complex I inhibition. BHB also increases 
acetyl-CoA levels in the mitochondria. The end result of having in-
creased ketone levels is improvement of mitochondrial efficiency and 
a decrease in the number of reactive oxygen species produced. For 
these reasons, the new drug caprylidene, which is an orally administered 
medium-chain triglyceride, is being used in the treatment of hypome-
tabolism in AD. Caprylidene is metabolized by the liver to the active 
ketone bodies BHB and ACA, providing an alternative energy source for 
the brain. Clinical trials of capylidene in patients with cognitive impair-
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ments that have been completed to date have proven that elevation in 
plasma BHB levels with an oral dose can improve memory and atten-
tion performance in individuals with memory and cognitive impairment. 
Caprylidene appears to be a safe method to elevate plasma levels of 
ketone bodies. 
Caprylidene is a medical food dispensed by prescription only that 
contains a formulation of medium chain triglycerides (MCTs). A medi-
cal food is defined as "a food which is formulated to be consumed or 
administered enterally or orally under the supervision of a physician, 
and which is intended for the specific dietary management of a disease 
or condition for which distinctive nutritional requirements, based on 
recognized scientific principles, are established by medical evaluation."5 
Caprylidene contains a formulation of caprylic triglyceride, which is an 
MCT for the clinical dietary management of the metabolic processes 
associated with mild to moderate AD.6 Patients should take 40 grams 
(one full packet) mixed in liquid once a day after breakfast or lunch. The 
most common adverse effects reported by patients in clinical studies 
were gastrointestinal in nature. Most reported were nausea, abdominal 
discomfort and diarrhea. 
This medical food was tested in trials that allowed subjects to remain 
on their prescribed medications for AD as long as they had been on a 
stable dose for at least three months. Most of the patients in these trials 
were receiving other medications for AD, including acetylcholinesterase 
inhibitors and/or NMDA receptor antagonists. It was determined that 
caprylidene can be administered as adjunctive therapy along with other 
AD medications. Caprylidene contains milk and soy, so it should not 
be used in patients that are allergic to either of these products. It also 
should be used with caution in patients with known hypersensitivity 
to palm or coconut oil and in patients at risk for ketoacidosis, such as 
alcoholics and uncontrolled diabetics. Also, elevated triglyceride levels 
were observed in patients who presented with probable metabolic 
syndrome; therefore, triglyceride levels should be monitored in patients 
with metabolic syndrome.6 
In a double-blind, placebo-controlled clinical trial, researchers tested 
the hypothesis that acute elevation of serum f3-hydroxybutyrate 
(f3-0HB) levels through an oral dose of MCTs would improve memory 
and attention in individuals with AD or mild cognitive impairments.7 
f3-0HB is a type of ketone body that appears to protect hippocampal 
neurons. The cognitive differences were examined between subjects 
with and without the APOE-e4 allele. Missing this allele is a genetic risk 
factor of sporadic AD. Results demonstrated that there was an increase 
in the Alzheimer's Disease Assessment Scale-Cognitive Subscale 
(ADAS-cog) within the e4- group (P=0.04). 
A randomized, double-blind, placebo-controlled, parallel-group study 
tested the hypothesis that ketosis could improve cognitive performance 
in AD. Clinicians administered a ketogenic compound to 152 patients 
with mild to moderate AD.8 The results demonstrated that, in the 
population that was missing the APOE- e4 allele, there was a signifi-
cant difference in ADAS-Cog scores versus placebo on two different 
instances (p=0.005 and p=0.0148). It was determined that the keto-
genic compound that was studied rapidly elevated serum ketone bodies 
in AD patients and thus resulted in significant differences in ADAS-Cog 
scores compared to placebo. 
Patients and their caregivers should be advised that mild GI symptoms 
may occur with caprylidene and should be taken following a meal 
containing fats and proteins so that the digestion of the MCTs occurs 
more slowly. Sipping the drink over a period of 30 minutes can improve 
tolerability rather than drinking it all at once. Some patients may require 
starting at a lower dose (~2 tbsp) and tapering up to a full dose. Also, 
over-the-counter medications such as simethicone, antacids and antidi-
arrheals can be useful for treating GI symptoms that may occur. 
Caprylidene is a novel therapeutic strategy because it treats one of the 
underlying causes of AD instead of treating the symptoms and progres-
sion of the disease. Because caprylidene is a safe treatment option with 
few side effects and no interactions with other AD medications, it can 
be initiated at almost any point in the treatment of AD depending on the 
physician's recommendations. In order for a patient to use caprylidene, 
they need to get a prescription from their physician and bring it into their 
pharmacy to be filled. Because this drug is so new, and in a relatively 
new class, further studies need to be conducted to prove the long-term 
efficacy of the medication and to solidify caprylidene's place in the treat-
ment of AD. 
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